Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults
Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...
Obesity
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...
Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity
Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...
Semaglutide Use Linked to Rare Eye Condition NAION in New Study
A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...
Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...
Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug
Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...
Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen
Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion
Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...
Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...
Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...
Eli Lilly Invests $5.3 Billion to Expand Manufacturing Capacity for Incretin Receptor Agonists
Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion...
Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity
Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...
Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...
Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials
At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...